股票編號 026 二零二五年度年報 | 公司資料 | 2 | | --- | --- | | 董事報告書 | 3-10 | | 環境、社會及管治報告 | 11-23 | | 企業管治報告 | 24-34 | | 董事局主席報告書 | 35-36 | | 董事及高級行政人員簡介 | 37-38 | | 獨立核數師報告 | 39-42 | | 綜合收益表 | 43 | | 綜合全面收益表 | 44 | | 綜合財務狀況表 | 45 | | 綜合權益變動表 | 46-47 | | 綜合現金流動表 | 48-49 | | 財務報表附註 | 50-86 | | 財政撮要 | 87 | | 集團物業 | 88 | 公司資料 董事局 執行董事 顏亨利醫生 主席 翁順來 行政總裁 Michael John MOIR 非執行董事 顏淑嫺醫生（於2025年6月2日獲委任） 獨立非執行董事 Anthony Grahame STOTT 陳智文 周明德醫生 Lynne Jane ARNETT（於2024年9月6日獲委任） 秘書 朱麗珊 註冊辦事處 香港北角英皇道510號港運大廈26樓2606-08室 銀行 香港上海滙豐銀行有限公司 渣 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中華汽車有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00026 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 45,218,856 | | 0 | | 45,218,856 | | 增加 / 減少 (-) | | | 0 | | 0 | ...

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Core Points - The company, China Automobile (00026), announced that it will distribute a final dividend of HKD 0.1 per share on February 6, 2026 [1]

Group 1 - The company, China Automotive (00026), announced that it will distribute a final dividend of HKD 0.1 per share on February 6, 2026 [1]

公告称，股东应占亏损收窄主要受惠于年中出售一项投资物业获利港币1.09亿元。 中华汽车(00026)发布截至2025年6月30日止年度全年业绩，营业额5306.3万港元，同比减少23.71%;除税 后股东应占亏损1.85亿港元，同比收窄29.64%;每股基本亏损4.08港元;拟派发末期股息每股0.1港元及特 别股息每股1.7港元。 ...

Core Viewpoint - The company reported a significant decline in revenue while managing to narrow its losses, primarily due to a profitable property sale [1] Financial Performance - The company's revenue for the year ending June 30, 2025, was HKD 53.063 million, representing a year-on-year decrease of 23.71% [1] - The net loss attributable to shareholders was HKD 185 million, which is a 29.64% improvement compared to the previous year [1] - Basic loss per share was HKD 4.08 [1] Dividend Announcement - The company proposed a final dividend of HKD 0.1 per share and a special dividend of HKD 1.7 per share [1] Key Factors - The reduction in net loss was mainly attributed to a profit of HKD 109 million from the sale of an investment property during the year [1]

於 本 公 告 ⽇ 期 ， 本 公 司 董 事 局 成 員 包 括 三 名 執 ⾏ 董 事 ， 分 別 為 顏 亨 利 醫 ⽣ 、 Michael John MOIR、 翁 順 來 ；⼀ 名 獨 ⽴ ⾮ 執 ⾏ 董 事 顏 淑 嫺 醫 ⽣ ； 及 四 名 獨 ⽴ ⾮ 執 ⾏ 董 事，分 別 為 Anthony Grahame STOTT、陳 智 文、周 明 德 醫 ⽣ 及 Lynne Jane ARNETT。 中 華 汽 ⾞ 有 限 公 司 （「 本 公 司 」）董 事 局 （「董 事 局 」） 公 布 ， 本 公 司 擬 對 本公司現 ⾏《 組 織章 程 細 則 》 內 容 作 出 若 ⼲ 修 訂（「該 建 議 修 訂 」）， 旨 在 （i） 配 合《 ⾹ 港 聯 合 交 易 所 有 限 公 司 證 券 上 巿 規 則 》（「《 上 巿 規 則 》」） 有 關 進 ⼀ 步 擴 ⼤ 無 紙 化 上 巿 機 制 的 修 訂；（ ii）為 本 公 司 提 供 靈 活 性 允 許 使 ⽤ 虛 擬 會 議 科 技 舉 ⾏ 股 東 ⼤ 會 ； （ iii）賦 予 董 事 局 及 股 東⼤ 會 主 席 權 ⼒，為 管 理 ...

Group 1 - The core viewpoint of the news is that China Automotive (00026.HK) reported a decrease in operating profit and a narrowed net loss for the fiscal year ending June 30, 2025, primarily due to reduced rental income from the sale of an investment property [1] - The group's operating profit for the fiscal year is HKD 77 million, down from HKD 95 million the previous year, reflecting a decrease in rental income [1] - The audited net loss attributable to shareholders after tax decreased from HKD 262 million to HKD 185 million, benefiting from a profit of HKD 109 million from the sale of an investment property [1] Group 2 - The group holds a 20% stake in Windcharm Property Holdings Limited, with the remaining 80% owned by a wholly-owned subsidiary of Swire Properties Limited [2] - Windcharm Property Holdings Limited is redeveloping the site into a mixed-use residential project named "Hyde Garden," with a total construction area of 64,500 square meters [2] - The development includes two sites connected by a pedestrian bridge, with Site A featuring a residential building with 258 units and a covered public transport terminal, while Site B will have two residential buildings with a total of 592 units, underground retail shops, and parking spaces [2]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，中華汽車有限公司董事局成員包括三名執行董事，分別為顏亨利醫生、Michael John MOIR及翁順來；一名非執行 董事顏淑嫺醫生；四名獨立非執行董事，分別為Anthony Grahame STOTT、陳智文、周明德醫生及Lynne Jane ARNETT。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 中華汽車有限公司 | | 股份代號 | 00026 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 2024/25年度特別股息通告 | | 公告日期 | 2025年9月29日 | | 公告狀 ...